A Mectizan Expert Committee (MEC) Statement on the use of Mectizan® during the COVID-19 pandemic:
The MEC reminds country partners that Mectizan is donated only for the elimination of onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis).
Declaración del Comité de Expertos de Mectizan (MEC) sobre el uso de Mectizan®:
El MEC recuerda a los países socios que Mectizan es donado únicamente para la eliminación de la oncocercosis (ceguera de los ríos) y la filariasis linfática (elefantiasis)
La pandemia de COVID-19 ha despertado el interés de los medios de comunicación y un incremento de las publicaciones sobre la acción de la ivermectina en la replicación viral del SARS-Cov-2.
Déclaration du Comité d’Experts de Mectizan (CEM) sur l’utilisation du Mectizan® :
Le Comité rappelle à nos pays partenaires que le Mectizan® est exclusivement donné pour l’élimination de l’onchocercose (cécité des rivières) et la filariose lymphatique (éléphantiasis).
Declaração do Comitê de Especialistas do Mectizan (CEM) sobre o uso de Mectizan®:
O Comitê lembra aos países parceiros que o Mectizan® é dado exclusivamente para a eliminação da oncocercose (cegueira do rio) e filariose linfática (elefantíase).
28 October 2020
The World Health Organization (WHO) announced in this week’s WHO Weekly Epidemiological Record that Malawi has been validated to have eliminated lymphatic filariasis as a public health problem.
This research article, co-authored by MDP’s Yao Sodahlon and Joni Lawrence, Merck’s Rachel Taylor, The Task Force for Global Health’s CEO, Dave Ross, and many NTD program managers, is focused on the need for building country capacity by increasing country ownership and domestic spending for NTD programs.
Sodahlon et al., 2020 (453.99 KB)
A recent study informed that ivermectin was successfully used in vitro for the treatment of SARS-CoV-2 in experimentally infected cells and two preprint publications on observational clinical studies reported the apparent utility of ivermectin to treat patients with COVID-19 needing mechanical ventilation; neither of these studies were peer-reviewed nor formally published and one of them was later retracted.
PAHO Recommendation Regarding the Use of Ivermectin as a Treatment for COVID-19 (381.44 KB)
The Mectizan Donation Program is committed to working towards WHO’s NTD Road Map 2030 targets and the path towards eliminating river blindness and lymphatic filariasis.
This short film covers the dedication of a community drug distributor on working towards eliminating onchocerciasis (river blindness) in Cameroon, Africa.
This research article is focused on the mapping of lymphatic filariasis (LF) in Loa loa endemic health districts in forest areas of Cameroon.
Beng et al., 2020 (1.68 MB)
This research article focuses on the results of four rounds of mass drug administration (MDA) for cross-border districts of Côte d’Ivoire where lymphatic filariasis (LF) is endemic.
Yokoly et al., 2020 (1.05 MB)
In order to confirm that transmission recrudescence or importation does not occur for lymphatic filariasis (LF) after mass drug administration (MDA), the WHO recommends post-treatment surveillance.
Eigege et al., 2020 (321.96 KB)
This research article examines the Ov16 (onchocerciasis) and Wb123 (lymphatic filariasis) seroprevalence in the Bakoye and Falémé foci in Mali after 24 – 25 years of treatment.
Dolo et al., 2020 (1.05 MB)
Mectizan Expert Committee Statement on Potential Efficacy of Ivermectin on COVID-19
A report by Caly et. al.* found that ivermectin has shown in vitro activity against SARS-COV-2 (COVID-19) in tissue culture with Vero-hSLAM cells.
This short film covers the movement to eliminate Onchocerciasis (river blindness) in Cameroon, Africa. Follow our Vimeo account for more video footage from the field.